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HDL THERAPEUTICS ABSTRACT
It has long been recognized that elevated levels of low-density 
lipoprotein cholesterol (LDL-C) increase the risk of cardiovascular 
disease (CHD) and that pharmacologic therapy to decrease LDL-C 
significantly reduces cardiovascular events. Despite the effectiveness 
of statins for CHD risk reduction, even optimal LDL-lowering therapy 
alone fails to avert 60% to 70% of CHD cases. A low plasma 
concentration of high-density lipoprotein cholesterol (HDL-C) is also 
associated with increased risk of CHD. However, the convincing 
epidemiologic data linking HDL cholesterol (HDL-C) to CHD risk in an 
inverse correlation has not yet translated into clinical trial evidence 
supporting linearity between HDL-C increases and CHD risk reduction. 
It is becoming clear that a functional HDL is a more desirable target 
than simply increasing HDL-C levels. Discoveries in the past decade 
have shed light on the complex metabolic and antiatherosclerotic 
pathways of HDL. These insights, in turn, have fueled the development 
of new HDL-targeted drugs, which can be classified according to four 
different therapeutic approaches: directly augmenting the 
concentration of apolipoprotein A-I (apo A-I), the major protein 
constituent of HDL; indirectly augmenting the concentration of apo A-I 
and HDL cholesterol; mimicking the functionality of apo A-I and 
enhancing reverse cholesterol transport. This review discusses the 
latest in novel HDL directed therapeutic strategies.
TOPIC: HDL C – Does it matter?
An update on novel HDL-C directed therapeutic strategies
INTRODUCTION:
  An estimated 16.3 million persons, or 7.6% of the United States 
population, have 
coronary heart disease (CHD) (1). Cardiovascular disease is responsible
for 811,940 
or 32.8% of all deaths in the United States on an annual basis (1). 
Focused risk 
reduction therapies are indicated for patients with CHD and those at 
significant risk to 
reduce events and improve survival rates.
The relationship between low density lipoprotein cholesterol (LDL-C) 
and high density 
lipoprotein cholesterol (HDL-C) and the development of CHD is widely 
acknowledged. 
In addition, the cardiovascular benefit for lowering LDL-C for those with
CHD is now 
well established (2). Current treatment strategies for reducing CHD risk
are insufficient 
to prevent most CHD events and suggest therapies for increasing 
HDL-C in addition to 
reducing LDL-C are necessary to prevent CHD events (3-5).
 However, the convincing epidemiologic data linking HDL-C and CHD 
risk has not yet translated into significant clinical trial evidence 
supporting linearity between HDL-C increases and CHD risk reduction. 
The recent negative results obtained in the ILLUMINATE and AIM-HIGH 
trials suggest that HDL-C increases may not always be beneficial (41, 
63). The results from these studies have led us to more questions than 
answers in our quest to reduce CHD events by improving HDL-C.
HDL FUNCTION
The knowledge of an inverse relationship between plasma levels of 
HDL-C and rates of CHD gained from epidemiological studies has long 
been held as a near guarantee that interventions that increase HDL-C 
will reduce CHD risk (6, 7). However, investigators in clinical trials have
so far failed to convey a mandate to increase HDL-C levels by a specific
degree or beyond a specific threshold to achieve protection against 
CHD events (8). Moreover, both genetic studies and clinical trials 
support the idea that, in some circumstances, HDL-C levels may 
behave opposite to what is predicted by the Framingham assessment 
model (9, 10). For example, carriers of the apoAI Milano mutation 
present with low levels of HDL-C but are resistant to 
atherosclerosis(11,12), whereas subjects with cholesteryl ester transfer
protein (CETP) deficiency have high HDL-C levels but are not patently 
protected against atherosclerosis(13-16). In addition, common 
polymorphisms in the CETP and hepatic lipase genes linked to elevated
HDL-C levels are associated with increased cardiovascular events (17, 
18).
These apparently contradictory findings may be explained by the 
notion that a ‘‘functional’’ HDL, rather than high plasma HDL-C 
concentration, is needed for a therapeutic effect. HDL functionality and
HDL-C concentrations likely go hand in hand in most people, but may 
diverge in the presence of specific mutations, in some disease states, 
or by the action of drugs (19-21). Therefore, newer therapies need to 
target HDL functionality rather than only HDL-C concentrations in the 
blood.
Mutations affecting the function of an enzyme rarely are linked to 
improved metabolism or health. Polymorphisms of both the CETP gene,
leading to high HDL-C levels through reduced cholesterol exchange, 
and the hepatic lipase gene, leading to high HDL-C levels through 
impaired lipolysis, have been linked to increased risk for CHD (17, 18). 
Indeed, a dysfunctional HDL is more likely associated with high, rather 
than low, HDL-C levels because it may often reflect altered recycling of 
the mature plasma HDL particle. Because of its high concentration, 
carrying a dysfunctional HDL may be more dangerous for vascular 
health than having low levels of functional HDL. Ansell et al (22) 
showed that patients with CHD and HDL-C greater than 85 mg/dL carry
dysfunctional HDL. A recent analysis of The Incremental Decrease in 
Endpoints through Aggressive Lipid Lowering trial (IDEAL) and 
European Prospective Investigation of Cancer-Norfolk observational 
study determined that the classic inverse correlation between HDL-C 
and CHD risk is not sustained when evaluating subjects with HDL 
greater than 70 mg/dL who appear to have increased CHD risk even 
when on statin therapy (23). CHD risk was also increased by the 
presence of large HDL particles, suggesting that dysfunctional reverse 
cholesterol transport with accumulation of lipid-loaded HDL in the 
plasma and high HDL-C levels is a pro-atherogenic condition (23).  Thus
it is becoming clear that a functional HDL is a more desirable target 
than simply increasing HDL-C levels.
A reason why so much emphasis is placed on the plasma HDL-C level 
as a predictor of vascular health is because it theoretically represents 
reverse cholesterol transport
(RCT), the system in charge of removing cellular cholesterol excesses 
from tissue sites of accumulation (24). The sub endothelial space of the
medium caliber artery is the most important tissue in this regard 
because accumulation of cholesterol-rich cells causes atheroma 
formation and the real target of therapy is to activate cholesterol exit 
from this very site. Because the essential function of HDL occurs in the 
extravascular space, and not in the plasma compartment, it is likely 
that plasma HDL-C levels have a limited power to predict RCT 
functionality in the target tissue. Moreover, HDL influences the 
atherogenic process not only through cholesterol extraction but also 
through anti-inflammatory and antioxidant properties (25).
However, what we test in plasma is almost exclusively the amount of 
cholesterol that the HDL has collected from tissues other than the 
arterial wall. If inappropriate amounts of HDL penetrate the plaque or if
the load of oxidized plaque lipids destabilizes HDL function, it is 
obvious that plasma HDL-C levels may be more and more disconnected
from CV risk prediction. This new knowledge on dysfunctional HDL has 
been termed a paradox because functionality is not directly linked to 
changes in HDL-C plasma concentrations (26). However, there is 
nothing paradoxical about it. RCT is necessary to remove excess 
cholesterol from peripheral cells in all tissues, a biologically essential 
function even if cholesterol trapping in the artery wall and the 
atherosclerotic process were not a common occurrence in humans. 
Plasma HDL-C levels represent the balance between  generation of 
mature HDL particles in the circulation and loss of lipid cargo via both 
HDL receptor (scavenger receptor type BI [SR-BI])-mediated transfer to
hepatocytes and CETP-mediated transfer to other lipoproteins.(27,28) 
Loss of lipid cargo is a desirable event because it leads to unloading of 
cholesterol and oxidized phospholipids in the liver and to the rebirth of 
the HDL particle for a new round of cholesterol acquisition. Therefore, a
high HDL-C level may mean enhanced production of mature HDL in the
plasma compartment (a good thing) or reduced loss of lipid cargo (not 
a good thing). Conversely, a low HDL-C level may signal increased loss 
of lipid cargo (a good thing) or reduced peripheral cholesterol 
collection (not a good thing).
HDL METABOLISM
HDL starts its life cycle as poorly lipidated apolipoprotein A1 (apoAI), 
which has a mandate to collect cellular cholesterol to avoid 
receptor-mediated degradation in the renal tubule (29, 30) (see Fig 1). 
ApoAI collects membrane cholesterol through multiple mechanisms, 
including specific ones requiring physical engagement with 
transmembrane lipid channels such as ATP-binding cassette 
transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1) 
and scavenger receptor class B member (SR-BI) (31). It is believed that
ABCA1 transfers phospholipids and cholesterol to the nascent HDL 
(32), whereas ABCG1 connects with larger HDL particles (33). SR-BI 
(also known as the hepatic HDL receptor) contributes significantly to 
lipid transfer from cells overloaded with cholesterol, such as arterial 
macrophages, and therefore may play a central role in atherogenesis 
(34). As free (unesterified) cholesterol translocates across the cell 
membrane, HDL esterifies it by adding a fatty acid chain via the action 
of lecithin cholesterol acyl-transferase (LCAT) (31). The nonpolar 
cholesteryl esters are then stored in the particle core. The core 
expansion leads to compositional maturation, yielding particles that 
predominate in plasma HDL. This sequence of changes means that 
HDL is heterogeneous in size because of variations in total lipid cargo 
and in the array of lipoproteins, enzymes, and other functional proteins
that can exist on its surface (35).
In the plasma compartment the mandate of the mature HDL switches 
from cholesterol acquisition to cholesterol delivery. This is achieved 
mainly via cholesteryl ester transfer protein (CETP)-mediated transfer 
of cholesterol to triglyceride-rich lipoproteins and via SR-BI mediated 
unloading of the cholesterol cargo in the liver. Plasma HDL that 
eliminates its lipid cargo can initiate a new cycle of peripheral 
cholesterol acquisition. This ‘‘reverse cholesterol transport-centric’’ 
view of HDL also encompasses the notion that its powerful anti-oxidant
and anti-inflammatory effects are linked to the collection and removal 
of oxidized lipids from both cellular membranes and LDL in the arterial 
wall (36).
NONPHARMACOLOGIC APPROACHES FOR RAISING HDL
The National Cholesterol Education Program (NCEP) Adult Treatment 
Panel III (ATP III) increased the definition of low HDL cholesterol from 
35mg/dl to 40mg/dl (37). Low HDL-C is also an important component of
the definition for metabolic syndrome, with cut points of 40mg/dl for 
men and 50mg/dl for women. The NCEP ATP III guidelines state that 
therapeutic lifestyle changes are the initial intervention for increasing 
HDL cholesterol. These therapeutic lifestyle change measures include 
reducing the dietary intake of cholesterol, increasing the use of plant 
stanols/sterols and fiber to lower LDL cholesterol, and moderating 
intake of calories and increasing physical activity to maintain desirable 
weight and cardiovascular fitness. Weight loss and smoking cessation 
are also advocated and can aid in raising serum levels of HDL. Dietary 
modification, including ingestion of omega-3 fatty acids via fish 
consumption or fish oil supplementation, has also demonstrated an 
effect in raising HDL-C. When therapeutic lifestyle changes are not 
adequate to increase serum HDL-C, pharmacologic therapy is often 
recommended.
PHARMACOLOGIC THERAPY
 When therapeutic lifestyle changes are not adequate to achieve target
goals, several pharmacologic therapy options exist for the 
management of low HDL-C (Table 1). It is well established that 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins) lower LDL-C, which significantly affects 
cardiovascular morbidity and mortality (2). Other non-LDL lipid effects 
of statins, including decreasing triglycerides and raising HDL-C, may 
also contribute to the risk reduction. Additional therapies with 
significant LDL lowering effects, such as fibrates and niacin, which 
lower triglycerides and raise HDL-C, also have been shown to reduce 
CHD events despite less potent effects on reducing LDL (38). As 
highlighted in the NCEP ATP III guidelines, consideration should be 
given to combination therapy with a fibrate or nicotinic acid in addition 
to a statin for high-risk patients with a low HDL-C level (see Fig 2).
STATIN THERAPY
First-line management of dyslipidemia in patients with cardiovascular 
disease is achieved with statin therapy. In patients with low HDL-C, 
statins are very effective in reducing the absolute cardiovascular event
rate (2). However, the residual risk of CHD events remains high. Statins
typically increase HDL-C levels by approximately 5% to 10%. Although 
the mechanism(s) by which statins raise HDL-C remains unclear, 
statins appear to reduce the supranormal rates of endogenous 
CETP-mediated cholesteryl ester transfer from HDL by decreasing the 
number of Apo B lipoprotein available to accept cholesteryl ester from 
HDL. Statins also appear to enhance hepatic Apo AI production, which 
may not occur with high-dose atorvastatin (80 mg) in which there is 
less HDL-C increase compared with similar LDL-C lowering by 
simvastatin or rosuvastatin. The clinical relevance of the difference in 
the HDL-C increase between atorvastatin 80 mg and rosuvastatin 40 
mg is being tested in the Study of Coronary Atheroma by Intravascular 
Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) trial, 
an intravascular ultrasound (IVUS) trial measuring plaque volume in 
CHD patients (39). 
NIACIN
Niacin, or nicotinic acid, is a soluble B vitamin that has favorable 
effects on all major lipid sub fractions but has limited use due to its 
side-effect profile.  Niacin was one of the first lipid-altering drugs to 
demonstrate a reduction in CHD events in the Coronary Drug Project 
(40). At present, niacin is identified as the most effective approved for 
raising HDL-C. In clinical studies, niacin has been demonstrated to 
lower LDL by 10% to 20%, triglyceride (TG) by 20% to 40%, and Lp (a) 
by 10% to 30%, as well as raise HDL by 15% to 30% (40). Niacin 
appears to increase HDL-C by decreasing the hepatic uptake of Apo AI, 
thereby delaying catabolism (41). Despite niacin being widely used in 
the management of dyslipidemia, the side effect of flushing of the face
and upper body can affect compliance to therapy. Flushing has been 
attributed as the major reason for discontinuation of therapy, 
estimated at rates as high as 25% to 40%The flushing that is induced 
by niacin is caused by the subcutaneous release of prostaglandin D2 
(PGD2), which is mediated by niacin’s action as a pharmacologic ligand
for the adipocyte and macrophage G protein coupled nicotinic acid 
receptor, GPR109A (42). The cutaneous vasodilation skin flush typically
starts in the face with a deep red coloration, usually accompanied by 
an intense feeling of warmth and itching, with occasional extension to 
the arms and chest. Although the duration of the flushing is generally 
less than 1 hour, the unpleasant sensation for patients can often affect
compliance and lead to therapy discontinuation.  Moderate doses of 
prostaglandin inhibitors have been demonstrated to reduce the 
cutaneous flushing response from niacin (43). Several additional 
strategies for reducing niacin induced flushing include regular 
consistent dosing, use of extended-release formulations, patient 
education, dosing with meals or at bedtime, and avoidance of alcohol, 
hot beverages, spicy foods, and hot baths or showers close to or after 
dosing. In comparison with immediate release niacin, extended-release
niacin results in reduced flushing as it is taken once a day at bedtime, 
when most flushing symptoms will occur when the patient is sleeping. 
However, the side effect profile includes the potential for liver toxicity 
(44). Other side effects include rash, flushing, gastrointestinal 
problems, worsening of esophageal reflux and gout, and headache 
(44). 
STATIN – NIACIN COMBINATION THERAPY
Combination therapy with a statin and niacin has been used to reduce 
residual cardiovascular risk after statin use by targeting both the 
lowering of LDL-C and increasing low HDL-C. Several clinical trials using
either immediate-release or extended-release niacin have 
demonstrated the efficacy and safety of this combination therapy in 
inhibiting the development of atherosclerosis (45). The Arterial Biology 
for the Investigation of the Treatment Effects of Reducing Cholesterol 
(ARBITER) 2 trial demonstrated that the addition of extended-release 
niacin to statin therapy resulted in an increase in HDL-C of 21% and 
slowed the progression of atherosclerosis as measured by a change in 
carotid intima-media thickness (CIMT), as compared with statin therapy
alone in patients with known CHD and low HDL-C levels (45). Although 
the ARBITER 2 trial showed slowing of progression of atherosclerosis, 
whether this translates to reduction of CHD events remains unclear.
The Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial was 
the first large-scale outcomes study to evaluate the impact of adding 
extended-release niacin to statin therapy (simvastatin) in patients with 
established coronary artery disease (46). The study was designed to 
test whether or not increasing HDL-C and lowering triglycerides in 
patients with low HDL-C and high triglycerides will reduce the risk of 
recurrent cardiovascular events in patients whose LDL-C was already 
within a desirable range with statin therapy.
AIM-HIGH  enrolled 3414 participants in the US and Canada , who were 
all prescribed simvastatin and then randomized to either high-dose, 
extended-release niacin in gradually increasing doses up to 2000 mg 
per day (n=1718) or placebo (n=1696). Of the participants, 515 were 
given a second LDL-cholesterol–lowering drug, ezetimibe (Zetia, 
Merck/Schering-Plough), in order to maintain LDL-cholesterol levels at 
the target range between 40 and 80 mg/dL.
 The primary end point for AIM-HIGH was a composite defined as time 
to first occurrence of any of the following: fatal or nonfatal myocardial 
infarction, ischemic strokes, hospitalizations for acute coronary 
syndrome or symptom driven coronary or cerebral revascularization 
procedures. Background therapy for all risk factors (blood pressure, 
blood glucose) was rigorous and met the goals set forth in the 
guidelines for high-risk patients. The addition of niacin to half of the 
patients did provide incremental HDL-C elevation and triglyceride 
reduction. However, the National Heart, Lung, and Blood Institute 
halted the trial prematurely because continuing was deemed futile 
after interim analyses showed no significant difference in adverse 
outcomes between the two groups (249 primary outcome events [15%]
in the simvastatin arm and 262 [15%] in the simvastatin/niacin arm; 
hazard ratio 1.053, 97.5% CI: 0.885-1.252; P=0.561). Moreover, 
investigators observed an excess hazard for ischemic stroke (28 vs. 12)
that was numerically, though not statistically, significant in the group 
receiving niacin.  Because of the small difference between treatment 
arms and the early termination of the trial, AIM-HIGH was 
underpowered to prove the hypothesis that niacin therapy may be 
beneficial in a secondary prevention population with controlled LDL-C. 
Therefore, the results of the study cannot be extrapolated to all 
patients with low HDL or all patients with uncontrolled LDL. The 
findings of AIM-HIGH will require careful study to determine if there are 
specific reasons for the failure of niacin to provide incremental risk 
reduction in this population of patients. The entire question of 
emerging science related to modulation of HDL in blood plasma is still 
being evaluated as new therapies beyond niacin are being developed. 
Ongoing pharmaceutical outcomes studies such as HPS2-THRIVE with 
over 25,000 patients may provide more insight regarding the efficacy 
of niacin in combination with statins to reduce CHD events.
The Heart Protection Study 2 Treatment of HDL to Reduce the 
Incidence of Vascular Events (HPS-2-THRIVE) is another large 
international trial of high-dose, extended-release niacin with 
simvastatin alone or in combination with ezetimibe in patients with 
established cardiovascular disease. The study is still ongoing, with 
results expected in 2013 (47)
STATIN-FIBRATE COMBINATION THERAPY
Statin-fibrate combination therapy is effective in reducing LDL-C and 
TG, and in increasing HDL-C. Fibrates are peroxisome 
proliferator-activated receptor-alpha (PPAR-a) ligands that lead to 
increased lipoprotein lipase expression and decreased Apo CIII 
expression. This results in enhanced catabolism of TG-rich particles. 
The expression of Apo AI and A-II are also increased by fibrates, with a 
net result of decreasing hypertriglyceridemia and increasing HDL-C. 
Due to these effects, fibrate combination therapy is used for patients 
with hypertriglyceridemia and low HDL. Statin- fibrate combination use 
is restricted, due to reports of rhabdomyolysis that mainly involved 
gemfibrozil and cerivastatin, which was voluntarily withdrawn from the 
market worldwide in 2001 after reports of fatal rhabdomyolysis.
 Fenofibrate or fenofibric acid is the fibrate of choice when used in 
combination with a statin because each is associated with a lower risk 
of myopathy than gemfibrozil. Several recent studies have 
demonstrated the efficacy and safety of fenofibric acid and statin 
therapy in patients with mixed dyslipidemia in reducing triglycerides 
and raising HDL-C compared with statin monotherapy.
NOVEL HDL-C DIRECTED THERAPEUTIC STRATEGIES
There are four different therapeutic approaches to improve HDL-C (see 
Table 2): 
1. Directly augmenting the concentration of apolipoprotein A-I (apo 
A-I), the major protein constituent of HDL
2. Indirectly augmenting the concentration of apo A-I and HDL-C
3. Mimicking the functionality of apo A-I 
4. Enhancing reverse cholesterol transport. 
1. Directly Augmenting Apo A-I Levels
Recombinant HDL: Lipid-poor apo A-I, also termed nascent HDL or 
preβ-HDL, initiates reverse cholesterol transport by activating 
macrophage (ABCA1) and accepting effluxed cholesterol. From a 
pharmacodynamic standpoint, direct augmentation of lipid-poor apo A-I
concentration arguably represents the most validated HDL-related 
therapeutic approach in terms of anti-atherogenic potential.
 Lipid-poor apo A-I–phospholipid complexes, sometimes referred to as 
recombinant HDL (rHDL), have been studied extensively in animals and
in preliminary studies in humans. Preclinical studies have 
demonstrated that the administration of apo A-I is associated with the 
inhibition or regression of atherosclerosis (51-54), enhanced 
macrophage-specific reverse cholesterol transport (55) and the inhibi-
tion of vascular inflammatory pathways (56). Moreover, short 
exploratory clinical studies of rHDL infusion have yielded decreases in 
coronary atherosclerosis, as assessed by coronary imaging, com-
parable with those obtained with long-term statin use at doses 
associated with improved clinical outcomes. These findings support the
therapeutic potential of intravenous apo A-I infusion (57, 58).
 ApoA-1 Milano: The apo A-I Milano mutation was first identified in a 
cohort of Italian patients who exhibited a decreased prevalence of 
atherosclerosis despite very low levels of HDL-C (10–20 mg/dl) (53). 
The effects of apo A-I Milano complexed with phospholipid 
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as 
ETC-216, have been studied in animals and humans (58). In support of 
an anti-atherogenic activity, infusions of ETC-216 in rabbit and mouse 
models of atherosclerosis were associated with considerable reductions
in the lipid and macrophage content of plaque (60-62).
In a small clinical study of 47 patients with acute coronary syndrome, 
five weekly doses of 15–45 mg/kg of ETC-216 significantly reduced 
total atheroma volume by 14.1 mm3 compared with baseline (4.2%; P 
<0.001), as measured by coronary intravascular ultrasonography 
(IVUS) (58) . Total atheroma volume did not change significantly with 
the administration of placebo (–0.2 mm3; P = 0.97). 
Wild type Apo A-I: Human plasma derived wild-type apoA-1 linked to 
soybean phospholipid (CSL111) was infused at 40 mg/kg per infusion in
humans in a small proof of concept trial (63). Five weekly infusions did 
not show a significant benefit on coronary plaque progression in 
comparison with placebo. However, when compared with pretreatment 
baseline, apoA-1 recipients showed regression in contradistinction to 
the placebo arm (63). The 80 mg/kg per infusion regimen was 
abandoned because of hepatic toxicity even though a single infusion of
80 mg/kg, in an unrelated study, was shown to favorably change 
femoral artery plaque composition (64). Overall, short-term infusion of 
synthetic HDL (containing apo A-I Milano or wild-type apoA-1) holds 
considerable promise as a potential strategy for rapid plaque 
remodeling and stabilization that could later be sustained with the use 
of orally LDL-C lowering and HDL-C raising agents, or even possibly 
repeated infusions. However, this requires further study.
Autologous Delipidated HDL: Another novel technique for 
increasing HDL-C involves the collection of 1 L of plasma by apheresis. 
The technique includes over 2 hours of apheresis followed by selective 
lipid removed from HDL using organic solvents to produce lipid-poor 
pre-b HDL. The lipid-poor pre-b HDL, which is a more efficient acceptor 
of cholesterol, is then reinfused back into the patient. In a small human
trial involving 28 patients with acute coronary syndrome, 7 weekly 
treatments resulted in a 5.2% decrease in atheroma volume compared 
with baseline (65). Small clinical trials using intravascular ultrasound of
the coronary arteries showed a similar 3.5% to 5% decrease in 
atheroma volume compared with baseline, but due to the small sample
sizes were not statistically significantly different from placebo.
2. Indirectly Augmenting Apo A-1 Levels
Oral Upregulator of Endogenous Apo A-1: RVX-208, an oral 
upregulator of endogenous Apo A-1 selectively induces nuclear 
transporter factors which in turn induces hepatic and intestinal 
production of Apo AI. This compound significantly increases HDL-C by 
more than 40% in monkeys, and the serum of treated animals was 
shown to enhance cholesterol efflux from foam cells (66). Significant 
increases in total plasma Apo AI were demonstrated in a small 
short-term human trial, but most of the increase was in pre-b HDL. 
RVX-208 was the first oral small molecule that stimulates Apo AI 
production to enter phase 2 trials. 
Niacin Receptor Agonists
Niacin, the first antidyslipidemic agent identified, remains the most 
potent drug in use for increasing levels of HDL-C and apo A-I. However,
the side effect of flushing of the face and upper body reduces 
compliance and leads to discontinuation of therapy in up to 25% to 
40% of patients (44).The discovery of the niacin receptor GPR109A90 
promised to usher in a new era in which the molecular mechanisms 
underlying the effects of niacin on lipids, and its adverse effects could 
be clearly defined (67). Co administration of the DP1 antagonist 
laropiprant reduces the incidence of the skin-related adverse effects of 
niacin (68). However, flushing still occurs in over half of the patients, 
and discontinuation of niacin treatment owing to severe skin-related 
symptoms remains a problem (69). A study in mice implicated 
keratinocyte-produced prostaglandin, PGE2 as a key mediator of 
niacin-induced skin flushing, suggesting that this molecule might be 
another potential target to minimize flushing (70, 71).
3. Mimicking Apo A-I Functionality
Another HDL-directed therapeutic approach utilizes small peptides that
mimic one or more of the functions of apo A-I (72, 73). The most 
well-studied apo A-I mimetic, 4F, consists of 18 amino acids designed 
to share the lipid-binding properties of apo A-I through a common 
secondary structure, the class A amphipathic helix (74). The only 
reported human study of D-4F to date hints at the possibility of a 
benefit for this compound in humans (75). Compared with HDL isolated
from individuals who received placebo, HDL isolated from individuals 
treated with a single 300 mg or 500 mg dose of unformulated D-4F 
increased the inhibition of LDL-induced monocyte chemotaxis in 
cultures of human aortic endothelial cells. As in animal studies, neither 
changes in apo A-I or HDL-C levels nor serious toxicity were observed 
in treated individuals.
4. Enhancing reverse cholesterol transport
CETP Inhibitors
 CETP plays an important role in cholesterol metabolism, as it is 
responsible for the transfer of cholesteryl esters from HDL-C to VLDL-C 
and LDL-C (see Figure 1). CETP is a very large protein and has a 
hydrophobic tunnel across the molecule that can accommodate neutral
lipid. CETP is a shuttle-type structure that promotes an equal mass 
gradient transfer of triglyceride for cholesterol ester between HDL and 
Apo-B lipoprotein (76). CETP plays an important role in maintaining a 
uniform distribution throughout the bloodstream and moves 
triglycerides where they are high (i.e., VLDL-C) to where they are low 
(HDL-C and LDL-C) in exchange for an equal mass gradient of 
cholesterol ester. Animals that lack CETP have very high HDL-C and 
very low LDL-C. CETP is important in modulating HDL size by 
redistributing cholesterol ester from triglyceride-rich particles into HDL 
particle. The triglyceride-enriched HDL is further acted on by hepatic 
lipase to form a smaller dense HDL that is more rapidly catabolized. 
CETP is also involved in transporting triglycerides in exchange for 
cholesterol ester from triglyceride-rich particles to LDL. LDL becomes 
triglyceride enriched and further hydrolyzed by the lipases to form a 
small dense atherogenic LDL. Theoretically inhibition of CETP should 
therefore result in beneficial effects on HDL-C and LDL-C which could 
translate into decreased atherogenesis and reduced cardiovascular 
events.
In  the  Investigation  of  Lipid  Level  Management  to  Understand  its
Impact in Atherosclerotic Events (ILLUMINATE) which involved patients
receiving atorvastatin were randomized to torcetrapib or placebo (77).
Torcetrapib worsened the primary combined cardiovascular end point
of death from coronary heart disease, nonfatal myocardial infarction,
stroke, and hospitalization for unstable angina (hazard ratio [HR] 1.25,
95% CI 1.09–1.44, P = 0.001) as well as all-cause mortality (HR 1.58,
95% CI 1.14–2.19, P = 0.006) compared with placebo after 12 months.
This was despite torcetrapib increasing HDL-C by 72% and decreasing
LDL-C by 25%. The worrisome results of ILLUMINATE were paralleled by
negative  imaging  findings  in  trials  in  which  coronary  and  carotid
ultrasonography  were  used  (78,  79).  These  negative  findings  have
been at least partly attributed to the off-target effects of torcetrapib,
such as the raising of  systolic  blood pressure by an average of 5.4
mmHg. As suggested by aldosterone measurements from participants
in  ILLUMINATE  (77),  findings  from  animal  models  (80)  and  human
adrenal cell assays (81) suggest these off-target effects may be related
to  stimulation  of  aldosterone  synthesis  by  torcetrapib  via  pathways
independent of CETP inhibition.
 Could inhibition of CETP activity explain some of the adverse effects
observed  in  the  clinical  development  program of  torcetrapib?  Initial
concerns  about  CETP  inhibition  highlighted  the  possibility  that  the
formation of large cholesterol-rich HDL particles resulting from CETP
inhibition  might  be  associated with  impaired cholesterol  efflux  from
peripheral  macrophages to these particles (82).  However,  studies of
patients  either  deficient  in  CETP  or  treated  with  a  CETP  inhibitor
demonstrated not reduced, but rather enhanced, efflux of cholesterol
via  ABCG1  to  HDL-C  (83,  84).  Thus,  an  important  step  of  reverse
cholesterol transport remains intact, if not improved, in the setting of
CETP inhibition.
 On  the  other  hand,  the  net  effect  of  CETP  inhibition  on  reverse
cholesterol transport might depend, in part, on the effects of CETP on
the hepatic uptake of HDL-derived cholesterol. The hepatic uptake of
HDL-C can be direct, or occur after transfer of HDL-C via CETP to apo
B-containing lipoproteins, which are then taken into the liver via the
LDL receptor. As illustrated by macrophage-specific reverse cholesterol
transport assays, in the setting of highly effective LDL clearance, CETP
can  actually  enhance  reverse  cholesterol  transport  and  have  an
atheroprotective role. However, when LDL clearance is impaired, CETP
can  slow  down  reverse  cholesterol  transport  and  thus  be
proatherogenic  (85).  The  interdependence  of  terminal  reverse
cholesterol transport pathways suggests that individuals who are most
likely  to  benefit  from  CETP  inhibition  are  those  with  suboptimal
LDL-receptor-mediated hepatic uptake of cholesterol. 
Fortunately,  at  least  two  novel  compounds  apparently  lacking  the
off-target  effects  of  torcetrapib  enable  further  testing  of  the
CETP-inhibition strategy, namely dalcetrapib and anacetrapib.
Dalcetrapib: Dalcetrapib binds CETP irreversibly and is considerably
less-potent  than  torcetrapib  (86). A  study  in  a  hamster  model
suggested  that  dalcetrapib  promotes  reverse  cholesterol  transport
(87). In a human study, among individuals with mean baseline HDL-C
and  LDL-C  levels  of  47  mg/dl  and  144  mg/dl,  respectively,  mono-
therapy with  600 mg of  dalcetrapib  daily  increased  HDL-cholesterol
levels by 23% compared with placebo administration, after 4 weeks of
treatment (88). Among patients with type II dyslipidemia receiving 40
mg of pravastatin daily and whose baseline levels of HDL-C and LDL-C
were 48 mg/dl and 120 mg/dl, respectively, the addition of 600 mg of
dalcetrapib  daily  increased  HDL-cholesterol  levels  by  28%  and
decreased  LDL-cholesterol  levels  by  7%  compared  with  placebo
administration,  after  4  weeks  of  treatment  (89). After  24  weeks  of
therapy with 900 mg of dalcetrapib daily, HDL-C levels increased by
33% (mean  baseline  level  of  42  mg/dl)  in  patients  at  high  risk  of
coronary  heart  disease events  who were  treated with  10–80 mg of
atorvastatin  daily,  when  compared  with  HDL  levels  in  participants
receiving placebo plus atorvastatin (90). LDL-C levels, however, did not
differ  in  the  two patient  groups (mean baseline  level  of  74 mg/dl).
Importantly, no changes in blood pressure or aldosterone levels were
observed with the use of high-dose dalcetrapib (900 mg).
Dal-PLAQUE (91) was a phase IIb, double-blind trial conducted at 11 
centers in patients  with CHD or CHD risk equivalents, treated with 
LDL-C lowering drugs to LDL-C <100 mg/dL (<2.6 mmol/L). Patients 
were randomized to dalcetrapib 600 mg or placebo daily for 24 
months, with a 2-week safety follow-up. Endpoints included indices of 
plaque burden from the right and left carotid and abdominal aorta 
determined by magnetic resonance imaging (MRI) after 24 months, 
and plaque inflammation using 18F-fluoro-deoxyglucose uptake 
measured by positron emission tomography/computed tomography 
(PET/CT) after 6 months. 189 subjects were screened and 130 
randomized into the trial. Based on MRI, a significant reduction in total 
vessel area and a trend towards reduction in average wall area were 
observed with dalcetrapib vs. placebo after 24 months (-4.01 mm2 
[-7.23, -0.80]; p=0.041 and -2.20 mm2 [-4.54, 0.13]; p=0.120 
respectively). Other indices of plaque burden were numerically reduced
from baseline with dalcetrapib versus placebo. Based on PET/CT, mean 
of maximum standardized uptake value and target to background ratio 
were unchanged with dalcetrapib versus placebo after 6 months. 
HDL-C increased by 31% with dalcetrapib after 24 months with no 
significant increases in inflammatory biomarkers. Dalcetrapib was well 
tolerated with a safety profile similar to placebo and was not 
associated with an increase in blood pressure.
Dal-PLAQUE 2 (92) will also assess changes in atherosclerotic plaque 
(morphology, composition, and inflammatory activity) among patients 
with CHD treated with 600 mg of dalcetrapib daily. 
Dal-VESSEL (93) was an exploratory phase IIb randomized, 
double-blind, placebo-controlled trial in patients with CHD or CHD risk 
equivalents, in which 476 patients with HDL-C levels <50 mg/dL were 
recruited. They received dalcetrapib 600 mg/day or placebo in addition
to their existing treatments. The primary efficacy endpoint was change
from baseline in brachial flow mediated dilation after 12 weeks. The 
primary safety endpoint was 24-hour ambulatory blood pressure 
monitoring assessed at week four. Patients were treated for a total 
period of 36 weeks. Results showed that dalcetrapib reduced CETP 
activity by almost 50% and increased HDL-C levels by 31% without 
changing nitric-oxide-dependent endothelial function or markers of 
inflammation and oxidative stress. Dalcetrapib did not increase 
24-hour ambulatory blood pressure (ABPM) at week 4, the primary 
safety endpoint.
 Finally, the phase III clinical trial Dal-Outcomes (94) will evaluate the 
effects of adding 600 mg of dalcetrapib daily to optimum 
pharmacotherapy in patients with acute coronary syndrome over a 2 
year follow up period, with results expected in 2013.
Anacetrapib: Anacetrapib inhibits CETP by forming a tight reversible 
bond (95). Healthy individuals with mean baseline HDL-C and LDL-C of 
51 mg/dl and 138 mg/dl, respectively after receiving 300 mg of 
anacetrapib daily for 10 days showed increases in HDL-C by 129% and 
decreases in LDL-C by 38% (96). No changes in blood pressure, 
assessed through 24 h ambulatory monitoring, were observed. Among 
patients with dyslipidemia who had mean baseline HDL-C and LDL-C of 
50 mg/dl and 141 mg/dl, respectively, addition of 300 mg of 
anacetrapib to 20 mg of atorvastatin daily for 8 weeks increased HDL-C
by 120% and decreased LDL-C by 30% compared with statin 
monotherapy (97). Interestingly, lipoprotein (a) levels, which were 
unchanged by statin therapy, decreased by 50% following anacetrapib 
administration.
The phase III Determining the Efficacy and Tolerability of CETP 
Inhibition with Anacetrapib (DEFINE) randomized, placebo-controlled 
trial examined the effect of 100 mg of anacetrapib administered daily 
for 18 months to 1623 CHD or CHD equivalent  patients who had 
achieved LDL-C treatment goals with statin therapy(98). The primary 
end points were the percent change in LDL-C at 24 weeks and the 
safety profile of anacetrapib at 76 weeks. HDL-C and other lipid 
parameters including lipoprotein (a) were assessed as secondary 
endpoints (94). Treatment with anacetrapib was associated with a 40% 
reduction in LDL-C from 81 mg/dl to 45 mg/dl (P <0.001) and a 138% 
increase in HDL-C from 41 mg/dl to 101 mg/dl (P <0.001) compared 
with placebo. Lipoprotein (a) decreased 36% compared with placebo 
from 27 nmol/l to 15 nmol/l. No increases in clinic-based blood 
pressure, serum aldosterone levels, or cardiovascular events were 
observed following anacetrapib treatment at 76 weeks. Supported by 
these substantial improvements in LDL-C, HDL-C, and lipoprotein (a), 
as well as an apparently benign safety profile, the Randomized 
EValuation of the Effects of Anacetrapib Through Lipid-modification 
(REVEAL) is scheduled to begin in April 2011(100). This study will 
examine major coronary events in 30,000 patients with coronary heart 
disease, cerebrovascular atherosclerotic disease, or peripheral artery 
disease (see Table 3).
Agonists of the Liver X Receptor
Liver X receptors (LXRs), which are members of the nuclear receptor 
superfamily, have a central role in lipid metabolism. Endogeneously 
activated by oxysterols, LXRs regulate the transcription of a myriad of 
target genes by binding to their promoters together with the retinoic 
acid receptor (101). With regard to HDL and reverse cholesterol 
transport, LXR activation has been demonstrated to promote 
mobilization of intracellular cholesterol (102), increase macrophage 
cholesterol efflux via macrophage ABCA1 and ABCG1 (103), and 
augment intestinal HDL generation (104).Therapeutic development of 
LXR agonists has been hindered by hepatic steatosis and increased 
plasma triglyceride concentrations reported in preclinical studies of 
these drugs (105).
Endothelial lipase inhibitors
Synthesized by and bound to vascular endothelial cells, endothelial 
lipase exhibits predominant phospholipase activity and affinity for HDL,
unique characteristics among the lipoprotein–lipase family (106). An 
association between the expression of endothelial lipase and 
HDL-cholesterol levels was identified in overexpression and 
loss-of-function mouse models (107-109).Genetic studies indicate a 
similar association in humans, with rare and low-frequency 
loss-of-function variants of endothelial lipase, identified through deep 
sequencing, resulting in elevated HDL-cholesterol levels (110). How 
changes in HDL-cholesterol levels attributed to endothelial lipase 
ultimately affect atherosclerosis remains uncertain. Some human 
studies point to an atherogenic role of endothelial lipase, with a 
positive association between plasma levels of this enzyme and 
coronary artery calcification, features of the metabolic syndrome (such 
as impaired fasting glucose, and waist circumference), and 
inflammation (111,112). Carriers of endothelial-lipase variants 
associated with raised HDL-cholesterol levels have been reported to 
have a decreased risk of atherothrombotic disease,(113) although this 
link has not been observed in other studies (114,115). Of note, animal 
studies have shown that HDL-cholesterol levels do not always correlate
with physiological changes associated with decreased atherosclerotic 
burden, with an endothelial-lipase knockout mouse model failing to 
demonstrate improved macrophage reverse cholesterol transport with 
raised HDL-cholesterol levels (116). More worrisome, in the setting of 
hepatic-lipase deficiency, is that the absence of endothelial lipase 
resulted in an accumulation of small dense LDL,(116) a particularly 
atherogenic subpopulation of LDL. These findings suggest that 
endothelial-lipase inhibition could potentially exert a detrimental effect
on atherosclerosis, even though HDL-cholesterol levels are raised. 
Despite this uncertainty, endothelial lipase has been the object of 
substantial interest as a therapeutic target. High-throughput screening 
identified several compounds sharing a sulfonyl furan urea core as 
potent and selective endothelial-lipase inhibitors (117). Further 
evaluation of these and other small-molecule inhibitors of endothelial 
lipase has not been performed yet.
Conclusions
Targeting HDL-C is an integral component of the management of CHD 
and risk reduction. Several strategies can be used to increase HDL-C 
levels to target cardiovascular risk reduction, including pharmacologic 
management focused on the use of statin, statin combination therapy, 
and investigational drugs targeting HDL-C metabolism and reverse 
cholesterol transport. However, the negative results obtained from the 
ILLUMINATE and AIM-HIGH clinical trials suggest that improving HDL-C 
levels in plasma alone does not necessarily translate into 
cardiovascular risk reduction. Due to the complexity of HDL cholesterol
metabolism and the wide variety of targets for improving HDL 
cholesterol levels, it is clear that further research is needed to 
determine which will be the safest, most cost-effective, and most 
efficacious for reducing both rates of atherogenesis and risk for acute 
cardiovascular events. Ongoing and future clinical trials will 
comprehensively evaluate these HDL cholesterol–raising therapies in 
patients in both the primary and secondary prevention settings.
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Table 1: Traditional drug therapy used to increase HDL-C
Drug 
Class
HDL-C 
Increase
Mechanism of Action Side Effects Clinical Trial 
Results
Statins 5%-15% 3-hydroxy-3-methyl-
glutaryl-CoA 
reductase 
(HMG-CoA) inhibitor
Myopathy, 
Increased 
liver 
enzymes.
Reduced major 
coronary events,
CAD deaths, 
need for 
coronary 
procedures, 
stroke and total 
mortality
Niacin 15%-35% Decreased 
clearance of ApoA1
Flushing, 
hepatotoxicit
y, 
hyperuricemi
a, upper 
gastrointestin
al distress, 
hyperglycemi
a
Reduced major 
coronary events
Fibrates 10%-20% Peroxisome 
proliferator- 
activated 
receptor-alpha 
(PPAR-α) agonist
Dyspepsia, 
gallstones, 
myopathy
Reduced major 
coronary events
Table 2:HDL- directed pharmacotherapeutic strategies
Directly augmenting apo A-1
Intravenous apo A-1 therapy
• Recombinant apoA-1 Milano/phospholipids (ETC-216)
• Purified native apoA-1/phospholipids (CSL-111/112)
• Autologous delipidated HDL
Indirectly augmenting apo A-1
• Oral upregulator of endogenous apoA-1 production (RVX-208)
• Niacin receptor (GPR109A) agonists
Mimicking Apo A1 Functionality
• Apo A-1 mimetic peptides
Enhancing reverse cholesterol transport
Cholesterol ester transfer protein inhibitors
• Dalcetrapib
• Anacetrapib
Liver X receptor agonists
Table 3: Ongoing late-stage clinical trials of HDL-directed therapies
Drug Trial Patient population (n) Anticipate
d 
completio
n date
CETP Inhibitors
Dalcetrapib DAL-Outcomes Acute coronary syndromes (15,600) 2013
Anacetrapib REVEAL Stable coronary heart disease or risk
equivalent (30,000)
2017
Niacin
Niacin-laropipr
ant
HPS2-THRIVE Stable vascular disease (25,000) 2013

Figure 2. Algorithm for the management of low serum high-density lipoprotein
(HDL) cholesterol. CAD - coronary artery disease; LDL - low-density 
lipoprotein; NCEP - National Cholesterol Education Program; TZD 
-thiazolidinedione. (Adapted from Circulation.22)
